Stockreport
Can This High-Yield Dividend Stock Keep Beating the S&P 500? [Yahoo! Finance]
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.amgen.com
Amgen (NASDAQ: AMGN) , a top-tier U.S. biotech firm, has been a coveted dividend stock since it began regular distributions to shareholders in 2011. Highlighting this fact, the company's shares have significantly outperformed the S&P 500 during this time. Can Amgen's stock continue to deliver excess returns relative to this benchmark index? Let's delve into the drugmaker's core value proposition to find out. Amgen: A reversal of fortune Amgen's shares have gotten off to a rocky start in 2024. Since the start of the year, the biotech's stock price has fallen by a hefty 8% compared to a nearly 7% gain for the S&P 500. Amgen's stock has come under pressure following a bull run in 2023. Investors bid up the biotech's stock by almost 10% last year in response to the excitement over its experimental weight loss candidate, MariTide. Early-stage data suggest MariTide might sport a dosing advantage over competing drugs in the category and, perhaps, a superior safety profile as well.
[Read more]
IMPACT SNAPSHOT | EVENT TIME: | AMGN | ||||
---|---|---|---|---|---|---|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
LAST PRICE | ||
VWAP | ||
High:
|
MAX UP |
High:
|
Low:
|
MAX DOWN |
Low:
|
%
|
POST NEWS RANGE |
%
|
|
PRICE CHANGE |
|
|
PRICE CHANGE PERCENTAGE |
|
|
S&P 500 (SPX) |
|
%
|
VOLUME RATIO |
%
|
VOLUME (SHARES) | ||
TICKS | ||
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
AMGN alerts
AMGN alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
NEWS
NEWS
- CytomX surges on upcoming data for Amgen-partnered cancer drug [Seeking Alpha][Seeking Alpha]
- AMGEN HIGHLIGHTS NEW COPD, ASTHMA AND VASCULITIS RESEARCH AT ATS 2024 [Yahoo! Finance][Yahoo! Finance]
- AMGEN HIGHLIGHTS NEW COPD, ASTHMA AND VASCULITIS RESEARCH AT ATS 2024[PR Newswire]
- Sandoz reaches agreement with Amgen over patent dispute [Reuters][Reuters]
- Hydronephrosis Treatment Market Size to Surpass US$4.31 Billion by 2033, The Brainy Insights [Yahoo! Finance][Yahoo! Finance]
- More
AMGN
SEC Filings
SEC Filings
- 4/26/24 - Form DEFA14A
- 4/17/24 - Form DEFA14A
- 4/17/24 - Form DEF
- AMGN's page on the SEC website
- More